Commentary

Dear Mr. Morgenthaler,

Thank you for the “Health & Wellness Update.” I look forward to each issue, and the solid information it provides.

Praise for
Smart Publications
Health & Wellness Update

"Wealth of information for anyone that chooses alternative healing methods. It's an education in itself just to read one of these newsletters! Every time I get one I read it from cover to cover! Easy to understand and easy to decipher when looking for products. Well done! It's a joy to read."

Smart Drugs & Nutrients:

How to Improve Your Memory and Increase Your Intelligence Using the Latest Discoveries In Neuroscience

VOLUME 1 in the Smart Drugs Series

by Ward Dean, M.D. & John Morgenthaler
$12.95 - 224 pages, softcover (Out of Stock)

• Table of Contents
• Previous Section
• Next Section
  

Section 4: Nootropics: More Doctors Recommend

Piracetam (Nootropil) | Aniracetam | Fipexide | Oxiracetam | Pramiracetam | Pyroglutamate (PCA) | Vinpocetine (Cavinton)

Vinpocetine (Cavinton)

Vinpocetine is a powerful memory enhancer. It facilitates cerebral metabolism by improving cerebral microcirculation (blood flow), stepping up brain cell ATP production (ATP is the cellular energy molecule), and increasing utilization of glucose and oxygen.

This graph represents comparative studies of vinpocetine and other smart drugs. (Redrawn from Gedeon Richter, Ltd. product literature.)

What all this means is that vinpocetine shares many of the effects of several other cognitive enhancers. In the above graph from a piece of drug company literature, vinpocetine is shown to compare favorably to: placebo, vincamine, papaverine, DHT (Hydergine), xanthinol nicotin­ate, meclo­phenoxate, cin­narizine, niacin, cyclandelate, difenidol, and ifenprodil.

Vinpocetine is often used for the treatment of cerebral circulatory disorders such as memory problems, acute stroke, aphasia (loss of the power of expression), apraxia (inability to coordinate movements), motor disorders, dizziness and other cerebro‑vestibular (inner-ear) problems, and headache. Vinpocetine is also used to treat acute or chronic ophthalmological diseases of various origin, with visual acuity improving in 70% of the subjects.

Vinpocetine also is used in the treatment of sensorineural hearing impairment.

The Gedeon Richter company of Hungary markets vinpocetine as Cavinton in Europe. They have funded more than one hundred studies on vinpocetine, often comparing its effects to other smart drugs. The incidence of side effects in humans using the drug orally is usually less than 1% of a study's participants, with the unwanted effects usually disappearing with continued use. One series of studies that Gedeon Richter conducted involved 882 patients with neurological disorders ranging from stroke to cerebral insufficiency. Significant improvements were found in 62% of the patients. In one of the studies, cerebral insufficiency patients were asked to memorize a list of 10 words. Without vinpocetine the subjects were able to memorize an average of 6 words. After a month of treatment the average went up to 10 words. Gedeon Richter promotes vinpocetine as the only drug that improves cerebral metabolism (glucose and oxygen uptake), tolerance of hypoxia (deficient blood oxygenation), ATP concentration, norepinephrine and serotonin turnover, and cerebral microcirculation. Gedeon Richter also claims that vinpocetine selectively increases blood flow to the brain, improving blood flow to the impaired area without lowering blood flow to other parts of the body (Gedeon Richter product literature).

As if the medical uses of vinpocetine were not amazing enough, in one double‑blind crossover study normal, healthy volunteers showed incredible short-term memory improve­ment an hour after taking 40mg of vinpocetine. The volun­teers took a computer‑administered short-term memory test called a Sternberg Memory Scanning Test. The volunteers (all women between the ages of 25 and 40) were shown one to three digits on a computer screen, then a moment later were shown a long string of digits. The volunteers then indicated whether any of the first digits appeared in the second long string. The time the volunteer took to remember was then assessed. On a placebo the women took an average of 700 milliseconds to respond when the first set contained 3 digits. With vinpocetine they averaged under 450 milliseconds! (Subhan, 1985).

Vinpocetine is a derivative of vincamine, which is an extract of the periwinkle. Although they have many similar effects vinpocetine has more benefits and fewer adverse effects than vincamine.

Percentage of patients taking vinpocetine whose symptoms of cerebrovas­cular disorders improved. (Redrawn from Gedeon Richter, Ltd. product literature.)

Precautions: Adverse effects are rare, but include hypoten­sion, dry mouth, weakness, and tachycardia. Vinpocetine has no known drug interactions, no toxicity, and is generally very safe.

Dosage: One or two 5 mg tablets per day.

Sources: Vinpocetine is not sold in the U.S. It can be purchased by mail order from the sources listed in Appendix A (see page 165). Other names include: ARGH‑4405, Cavinton, Ceractin.

References:

DeNoble, V.J., Repetti, S.J., Gelpke, L.W., Wood, L.M., Keim, K.L. "Vinpocetine: Nootropic Effects on Scopolamine‑Induced and Hypoxia‑Induced Retrieval Deficits of a Step‑Through Passive Avoidance Response in Rats." Pharmacology Biochemistry & Behavior. 1986, Vol. 24, pp. 1123‑8.

Gedeon Richter product literature, Cavinton.

Hadjiev, D., Yancheva, S. "Rheoencephalographic and Psychologic Studies with Ethyl Apovincaminate in Cerebral Vascular Insufficiency." Arzneimittel­forschung. 1976, Vol. 26, pp. 1947‑50.

Otomo, E., Atarashi, J., Araki, G., Ito, E., Omae, T., Kuzuya, F., Nukada, T., Ebi, O. "Comparison of Vinpocetine with Ifenprodil Tartrate and Dihydroergotoxine Mesylate Treatment and Results of Long‑Term Treatment with Vinpocetine." Current Therapeutic Research. 1985, Vol. 37, No. 5, pp. 811‑21.

Pelton, R., Pelton, T.C. Mind Food & Smart Pills. New York: Double­day, 1989.

Subhan, Z., Hindmarch, I. "Psychopharmacological Effects of Vinpocetine in Normal Healthy Volunteers." Europe­an Journal of Clinical Pharmacology. 1985, Vol. 28, pp. 567‑71.